We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · June 18, 2020

Estriol Vaginal Gel in HR+ Postmenopausal Women With Early-Stage Breast Cancer Treated With Nonsteroidal AIs

The Oncologist


Additional Info

The Oncologist
A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
Oncologist 2020 May 27;[EPub Ahead of Print], P Sánchez-Rovira, AL Hirschberg, M Gil-Gil, B Bermejo-De Las Heras, C Nieto-Magro

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading